A modular IgG-scFv bispecific antibody topology

KD Orcutt, ME Ackerman, M Cieslewicz… - … , Design & Selection, 2010 - academic.oup.com
Here we present a bispecific antibody (bsAb) format in which a disulfide-stabilized scFv is
fused to the C-terminus of the light chain of an IgG to create an IgG-scFv bifunctional antibody. …

Highly avid magnetic bead capture: an efficient selection method for de novo protein engineering utilizing yeast surface display

…, D Levary, G Tobon, B Hackel, KD Orcutt… - Biotechnology …, 2009 - Wiley Online Library
Protein engineering relies on the selective capture of members of a protein library with
desired properties. Yeast surface display technology routinely enables as much as million‐fold …

A gradient-loadable 64Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography

H Lee, J Zheng, D Gaddy, KD Orcutt, S Leonard… - … , Biology and Medicine, 2015 - Elsevier
Effective drug delivery to tumors is a barrier to treatment with nanomedicines. Non-invasively
tracking liposome biodistribution and tumor deposition in patients may provide insight into …

Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging

KD Orcutt, AL Slusarczyk, M Cieslewicz… - Nuclear medicine and …, 2011 - Elsevier
INTRODUCTION: In pretargeted radioimmunotherapy (PRIT), a bifunctional antibody is
administered and allowed to pre-localize to tumor cells. Subsequently, a chelated radionuclide is …

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies

…, JJ Orozco, BG Till, KD Orcutt… - Blood, The Journal …, 2018 - ashpublications.org
Pretargeted radioimmunotherapy (PRIT) has demonstrated remarkable efficacy targeting
tumor antigens, but immunogenicity and endogenous biotin blocking may limit clinical …

Effect of Small-Molecule–Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody

KD Orcutt, JJ Rhoden, B Ruiz-Yi, JV Frangioni… - Molecular cancer …, 2012 - AACR
Small-molecule ligands specific for tumor-associated surface receptors have wide applications
in cancer diagnosis and therapy. Achieving high-affinity binding to the desired target is …

[HTML][HTML] Dynamic dual-isotope molecular imaging elucidates principles for optimizing intrathecal drug delivery

DA Wolf, JY Hesterman, JM Sullivan, KD Orcutt… - JCI insight, 2016 - ncbi.nlm.nih.gov
The intrathecal (IT) dosing route offers a seemingly obvious solution for delivering drugs
directly to the central nervous system. However, gaps in understanding drug molecule behavior …

A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance

…, L Li, JT Andersen, I Sandlie, KD Orcutt… - … , Design & Selection, 2013 - academic.oup.com
A series of anti-tumor/anti-chelate bispecific antibody formats were developed for pre-targeted
radioimmunotherapy. Based on the anti-carcinoembryonic antigen humanized hT84.66-…

Comparative analysis of bispecific antibody and streptavidin-targeted radioimmunotherapy for B-cell cancers

…, TA Gooley, JJ Orozco, BG Till, S O'Steen, KD Orcutt… - Cancer research, 2016 - AACR
Streptavidin (SA)-biotin pretargeted radioimmunotherapy (PRIT) that targets CD20 in non-Hodgkin
lymphoma (NHL) exhibits remarkable efficacy in model systems, but SA …

Molecular simulation of receptor occupancy and tumor penetration of an antibody and smaller scaffolds: application to molecular imaging

KD Orcutt, GP Adams, AM Wu, MD Silva… - Molecular imaging and …, 2017 - Springer
Purpose Competitive radiolabeled antibody imaging can determine the unlabeled intact
antibody dose that fully blocks target binding but may be confounded by heterogeneous tumor …